Overview

Next Generation Pneumococcal Vaccines: What You Need to Know

Pneumococcal Vaccines: Conference Highlights

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Format

Symposium Highlights

Time to Complete

1.00 hr(s).

Release Date

May 27, 2022

Expires On

May 27, 2023

What’s new with pneumococcal vaccines? In 2021, two exciting, next-generation pneumococcal vaccines have become available. Expert faculty from Loma Linda University, the University of Pittsburgh School of Medicine, and the Lewis Katz School of Medicine at Temple University recently led a symposium at a major internal medicine meeting outlining the characteristics and latest recommendations with these novel vaccines. Learn how to overcome present barriers with vaccine uptake (particularly amidst the ongoing COVID-19 pandemic), and the key serotypes most responsible for invasive pneumococcal disease. Don’t throw away your shot! View these important highlights.

UPDATE 6/22/22: PCV15 is now also approved for children 6 weeks through 17 years of age.

This activity is intended for internal medicine physicians, pharmacists, and other clinicians who manage adult patients for whom pneumococcal vaccination is recommended.

HCPs lack knowledge of the shifting epidemiology and serotype distribution of invasive pneumococcal disease. Clinicians also require up-to-date knowledge of ACIP recommendations for pneumococcal immunization and best practices in introducing CDC recommendations into practice. Finally, clinicians require strategies to engage and guide patients through shared decision-making and identify missed opportunities for vaccination. This educational initiative provides a means for clinicians to overcome these knowledge and competency gaps.

Upon completion of this activity, participants will be able to:
• Explain the rationale behind the development of next-generation pneumococcal vaccines
• Identify highest-risk groups who should receive a pneumococcal vaccine
• Formulate strategies to engage patients and encourage pneumococcal vaccine uptake
• Outline the latest ACIP recommendations for pneumococcal vaccination

This activity is supported through an Independent Medical Education grant from Merck & Co., Inc..

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

• Introduction
• Adult Vaccinations: Current Affairs
• Next-Generation Pneumococcal Vaccines
• Case-based Learning Experience
• Strategies to Facilitate Pneumococcal Vaccine Uptake
• Questions and Answers

Michael Hogue, PharmD, FAPhA, FNAP
Dean and Professor
Loma Linda University - School of Pharmacy
Professor of Preventive Medicine, School of Medicine
Director, Center for Interprofessional Education & Practice
Loma Linda University
Loma Linda, CA

Donald Middleton, MD

Professor of Family Medicine

University of Pittsburgh School of Medicine

UPMC St. Margaret

Pittsburgh, PA

Margot Savoy, MD, MPH, FAAFP

Associate Professor of Family & Community Medicine

Associate Professor of Urban Bioethics & Population Health

Lewis Katz School of Medicine at Temple University

Philadelphia, PA

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Michael Hogue, PharmD, FAPhA, FNAP

No financial relationships to disclose

Donald B. Middleton, MD

Advisor or Review Panel member: Pfizer Inc.

Consultant (occasional): Pfizer Inc.

Speaker Bureau: Pfizer Inc.

Margot Savoy, MD, MPH, FAAFP

Advisory Panel: Eisai

Independent Contractor: Merck & Co., Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME and ACPE Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Pharmacists should consult with their state pharmacy on pharmacist vaccination authority included within their scope of practice.

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 1.0 contact hour.

ACPE Universal Activity Number: 0396-0000-22-035-H06-P

Activity Type(s): Application

Release Date: May 27, 2022

Expiration Date: May 27, 2023

Michelle Forcier
mforcier@achlcme.org

Overview

Next Generation Pneumococcal Vaccines: What You Need to Know

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Hardware and Software Requirement

Agenda

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities